Evidence map›Paper›PMID 39609755›Full record

ArticleBMC musculoskeletal disorders2024

Validity evaluation of a rat model of monoiodoacetate-induced osteoarthritis with clinically effective drugs.

Yamato Sasaki, Kei Kijima, Keiji Yoshioka

Abstract readValidation Study
In one paragraph

Article in BMC musculoskeletal disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. REJENERAInflammopharmacology · 2026
    Article
  5. Chondroprotective Effects of Enzyme-Treated Extract fromInternational journal of molecular sciences · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yamato SasakiCentral Research Laboratory, Research & Development Division, Seikagaku Corporation, Tateno 3-1253, Higashiyamato-shi, Tokyo, 207-0021, Japan. yamato.sasaki@seikagaku.co.jp.
Kei KijimaCentral Research Laboratory, Research & Development Division, Seikagaku Corporation, Tateno 3-1253, Higashiyamato-shi, Tokyo, 207-0021, Japan.
Keiji YoshiokaCentral Research Laboratory, Research & Development Division, Seikagaku Corporation, Tateno 3-1253, Higashiyamato-shi, Tokyo, 207-0021, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKnee osteoarthritis (KOA) is the most common type of joint disease in elderly people and is characterized by pain and dysfunction. Although the monoiodoacetate (MIA)-induced model is widely used as a rodent KOA model, it is important to acknowledge the inherent limitations of this model, as the MIA model develops complex pathological phases on a daily basis. An accurate understanding of this model and the selection of an appropriate time point according to the target for drug candidates can lead to the development of clinically effective drugs.

methodsChanges in the pathological state of the MIA model were assessed via histopathological evaluation. Clodronate, a bisphosphonate, and diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), were selected as models of clinically effective drugs due to their different mechanisms of action. The analgesic effects of both drugs on the MIA model were evaluated. The long-term effect of clodronate on subchondral bone osteoclasts was also evaluated.

resultsHistopathological evaluation revealed that MIA-induced symptomatic behavior occurred in the early and late phases and was accompanied by synovial inflammation and osteoclast-related joint degeneration, respectively. Although clodronate inhibited symptomatic behavior and prevented cartilage degeneration from the early to late phases, diclofenac inhibited symptomatic behavior only in the early phase. Clodronate acted locally and inhibited the activation of subchondral osteoclasts.

conclusionsPathological changes, such as synovial changes in the early phase and knee joint degeneration in the late phase, in the MIA model are similar to those in human KOA. Our results indicate that the early phase in the MIA model is appropriate for evaluating the effects of anti-inflammatory agents such as NSAIDs and corticosteroids. The late phase in the MIA model is appropriate for evaluating the effects of drugs that act on cartilage and subchondral bone.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalClodronic AcidDiclofenacDisease Models, AnimalIodoacetic AcidAnimalsArthritis, ExperimentalBone Density Conservation AgentsMaleOsteoarthritis, KneeOsteoclastsRatsRats, Sprague-DawleyAnti-Inflammatory Agents, Non-SteroidalBone Density Conservation AgentsClodronic AcidDiclofenacIodoacetic AcidCartilageClodronateDiclofenacMonoiodoacetateOsteoarthritisOsteoclastPainSynovium

Identifiers

PMID39609755
PMCPMC11605887

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.